AZD0305

Phase 2

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

AZNPhase 2$256.5B

AZD0305 Phase 2 Est. Readout

AZD0305• Multiple Myeloma226

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

20 competitors in Multiple Myeloma

BMYcilta-cel

DFPHCAR T Cell Therapy

CHCTramantamig

CHCTciltacabtagene autoleucel

ADPTMRD Testing

View Full Landscape

Drug Information

Target Indication

Multiple Myeloma

Clinical Trial

NCT06106945

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Capivasertib plus DocetaxelPhase 3

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Bacillus Calmette-Guerin (BCG)Phase 3

Non-muscle-invasive Bladder Cancer

Docetaxel Injectable SolutionPhase 3

Metastatic Castration-resistant Prostate Cancer (mCRPC)

AZD 1222Phase 3

COVID-19

Paclitaxel and CarboplatinPhase 3

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts